<DOC>
	<DOCNO>NCT01257334</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 10773 ( 10 mg , 25 mg / daily ) compare placebo give 24 week add-on therapy metformin metformin plus sulfonylurea patient T2DM insufficient glycaemic control . Open-label arm : estimate efficacy safety 25 mg BI 10773 poorly control patient ( HbA1c &gt; 10 % )</brief_summary>
	<brief_title>Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone Metformin Combination With Sulfonylurea</brief_title>
	<detailed_description>Concomitant medication , include treatment use treat intercurrent medical condition treatment period , record CRFs . This record include name medication , frequency , unit dose , dosage , date drug start stop , indication use drug . Prohibited The following treatment prohibit trial 1 . Other antidiabetic agent except background therapy ( metformin combination metformin plus sulfonylurea ) 2 . Treatment anti-obesity drug systemic steroid 3 . Other investigational medication</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus prior inform consent Male female patient diet exercise regimen pretreated immediate release metformin immediate release metformin plus sulfonylurea ( see minimum dos ) . The treatment regimen unchanged 12 week prior randomisation . 1 . Minimum dose metformin : ≥1500 mg/day maximum tolerate dose maximum dose accord local label 2 . Minimum dose sulfonylurea : ≥half maximal recommend dose maximum tolerate dose maximum dose accord local label HbA1c ≥ 7.0 % ≤ 10 % Visit 1 ( screen ) order eligible randomize treatment . HbA1c &gt; 10 % Visit 1 ( screen ) order eligible openlabel treatment arm ( 25 mg BI 10773 ) Age ≥ 18 BMI ≤ 45 kg/m2 ( BodyMass Index ) Visit 1 ( Screening ) Signed date write informed consent date Visit 1 accordance GCP local legislation Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) Any antidiabetic drug within 12 week prior randomisation except mention inclusion criterion 2 Acute coronary syndrome include myocardial infarction , stroke TIA within 3 month prior inform consent Indication liver disease , define serum level either ALT ( SGPT ) , AST ( SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen and/or runin phase Impaired renal function , define eGFR &lt; 30 ml/min ( severe renal impairment ) determine screen and/or runin phase Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year Contraindications metformin and/or sulfonylurea accord local label patient enter study respective background therapy Blood dyscrasia disorder cause haemolysis unstable Red Blood Cell ( e.g.malaria , babesiosis , haemolytic anaemia ) Treatment antiobesity drug ( e.g . sibutramine , orlistat ) 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2D Premenopausal woman ( last menstruation ≤ 1 year prior informed consent ) : nursing pregnant childbearing potential practicing acceptable method birthcontrol , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence ( acceptable local authority ) , double barrier method vasectomise partner Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake Participation another trial investigational drug within 30 day prior informed consent Any clinical condition would jeopardize patient safety participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>type 2 diabetes</keyword>
</DOC>